| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00401-015-1489-X |
| P698 | PubMed publication ID | 26467270 |
| P50 | author | Michael W Parker | Q41147578 |
| Jens Wiltfang | Q42165310 | ||
| Jose S Lopez-Noguerola | Q88139222 | ||
| P2093 | author name string | Gabriela A N Crespi | |
| Luke A Miles | |||
| Thomas A Bayer | |||
| Yvonne Bouter | |||
| Petra Tucholla | |||
| P2860 | cites work | Amyloid plaque core protein in Alzheimer disease and Down syndrome | Q24568384 |
| Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease | Q24672501 | ||
| Immunotherapy for Alzheimer's disease: hoops and hurdles | Q26823877 | ||
| Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation | Q27676409 | ||
| Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab | Q27684692 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain | Q28137790 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease | Q29617986 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 | ||
| Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model | Q30478167 | ||
| Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model | Q30489966 | ||
| Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis | Q30497751 | ||
| Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease | Q30512697 | ||
| Brain amyloid-β oligomers in ageing and Alzheimer's disease | Q30539133 | ||
| Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach | Q31144656 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide | Q33630090 | ||
| Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis | Q33777535 | ||
| Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease | Q33851064 | ||
| Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline | Q33895797 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies | Q34472054 | ||
| Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology | Q35747757 | ||
| Intraneuronal Abeta42 accumulation in human brain. | Q35793325 | ||
| Disaggregation of Alzheimer beta-amyloid by site-directed mAb. | Q36109944 | ||
| Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ. | Q36342011 | ||
| Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study | Q36984142 | ||
| N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits | Q37043304 | ||
| Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models | Q37062829 | ||
| Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 | ||
| Reassessing the amyloid cascade hypothesis of Alzheimer's disease | Q37187966 | ||
| Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases | Q37461136 | ||
| N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody | Q37485472 | ||
| 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study | Q37699953 | ||
| The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes | Q37979641 | ||
| Solanezumab for the treatment of mild-to-moderate Alzheimer's disease | Q37979840 | ||
| Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future | Q38161675 | ||
| Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? | Q38180298 | ||
| Immunotherapy for Alzheimer's disease: past, present and future | Q38222750 | ||
| Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease | Q38230386 | ||
| Truncated and modified amyloid-beta species | Q38230390 | ||
| Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease | Q38473766 | ||
| Resolving controversies on the path to Alzheimer's therapeutics | Q39709721 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? | Q42021752 | ||
| Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains | Q43517947 | ||
| Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. | Q43941772 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy | Q44708254 | ||
| Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro | Q46109204 | ||
| Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels | Q46244500 | ||
| An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. | Q47393680 | ||
| A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice | Q48264364 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. | Q48404445 | ||
| Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. | Q48468481 | ||
| Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific | Q48646949 | ||
| Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition | Q48713890 | ||
| Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice | Q48855353 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. | Q48912014 | ||
| Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. | Q50681098 | ||
| The Global Deterioration Scale for assessment of primary degenerative dementia | Q57279034 | ||
| P433 | issue | 5 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 713-729 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models. | |
| P478 | volume | 130 |
| Q60916157 | 18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer’s Disease |
| Q90893924 | A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease |
| Q48222289 | Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier |
| Q49762112 | Alzheimer's disease hypothesis and related therapies |
| Q47975769 | An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease |
| Q96816038 | Analyzing microglial-associated Aβ in Alzheimer's disease transgenic mice with a novel mid-domain Aβ-antibody |
| Q54982684 | Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. |
| Q37609644 | Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? |
| Q90477691 | Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration |
| Q42317412 | Erratum to: Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? |
| Q37652424 | Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway |
| Q92652983 | New treatment modalities in Alzheimer's disease |
| Q37697832 | Protein misfolding in neurodegenerative diseases: implications and strategies |
| Q46348872 | Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy |
| Q95266895 | Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice |
| Q42655652 | UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease |
Search more.